Academic Editor: Peter A. McCullough
Our objective was to systematically evaluate the efficacy and safety of proton
pump inhibitors combined with clopidogrel in patients undergoing percutaneous
coronary intervention and to provide an evidence basis for clinical treatment
decision-making. The database EMBASE, PubMed/Medline, Web of Science, the
Cochrane Library and CNKI records from establishment of each database until
August 2020 were included. Articles were evaluated for quality. Meta-analysis of
selected articles was conducted by RevMan5.3 software. Three RCTs and 4 cohort
studies were included, with a total of 9932 patients. Four studies reported
gastrointestinal (GI) bleeding events, 3 of which were RCT studies. Overall,
there was a significantly lower risk of GI bleeding events in the PPI group
compared to the no PPI group [OR = 3.06, 95% CI: 1.89 to 4.95] (P